The joint sales of the combined companies were about $3.5 billion; they had about 9,500 employees and owned more than 3,600 licenses and patents.

[6] In 2013, they launched a project called Claritas Genomics in partnership with Boston Children's Hospital.

With Children's as a major shareholder, Claritas Genomics merged the knowledge, resources, and employees of the Genetic Diagnostic Lab at the Boston hospital, a CLIA-certified facility that provided more than 100 genetic tests, including numerous specific diagnostics created at Boston Children's.

It also made use of the Ion Proton Sequencer from Life Technologies, a precise benchtop device that might be scaled for widespread use in new assays.

[8] A court case involving Life Technologies (as the former Applera Corp) ended in January 2014, as the Connecticut District Court penalized Life Technologies Corp over $60 million[9] for patent infringements by its parent companies prior to the merger.